Autor:
Kopp, N.
Díaz, D.
Amacker, M.
Odongo, David O.
Beier, K.
Nitsch, C.
Bishop, Richard P.
Daubenberger, C.A.
The BM86 antigen, originally identified in Rhipicephalus (Boophilus) microplus, is the basis of the only commercialized anti-tick vaccine. The long-term goal of our study is to improve BM86 based vaccines by induction of high levels of tick gut binding antibodies that are also cross-reactive with...
Enlace original:
https://cgspace.cgiar.org/handle/10568/381
Kopp, N.
,
Díaz, D.
,
Amacker, M.
,
Odongo, David O.
,
Beier, K.
,
Nitsch, C.
,
Bishop, Richard P.
,
Daubenberger, C.A.
,
[Identification of a synthetic peptide inducing cross-reactive antibodies binding to Rhipicephalus (Boophilus) decoloratus, Rhipicephalus (Boophilus) microplus, Hyalomma anatolicum anatolicum and Rhipicephalus appendiculatus BM86 homologues]
,
Identification of a synthetic peptide inducing cross-reactive antibodies binding to Rhipicephalus (Boophilus) decoloratus, Rhipicephalus (Boophilus) microplus, Hyalomma anatolicum anatolicum and Rhipicephalus appendiculatus BM86 homologues
